Broadcast Date: November 18, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

IncellDx specific companion diagnostic tests can determine the efficacy and dosing by using leronlimab (monoclonal antibody under flow cytometry) in severe cases of COVID-19 to determine presence of CCR5. Evaluation of test results found that patients with severe COVID-19 disease are in the midst of immunologic chaos which includes the cytokine storm. IncellDx’s companion diagnostics show that after three days of therapy, the immune profile in these patients approach normal levels and the levels of cytokines involved in the cytokine storm are much improved. Droplet Digital PCR (ddPCR) meets both testing needs for sensitivity and precision and has emerged as a go-to method for assessing the quality of patient-derived DNA samples from plasma. In this Clinical OMICs webinar, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for treatment of COVID-19.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

 

Produced with support from:

Bruce Patterson, PhDBruce Patterson, PhD
Founder and Chief Executive Office
IncellDx